Home » Stocks » UROV

Urovant Sciences Ltd. (UROV)

Mar 29, 2021 - UROV was delisted (reason: acquired by Sumitovant Biopharma)
Stock Price: $16.24 USD 0.00 (0.00%)
Updated Mar 26, 2021 4:00 PM EDT
Market Cap 531.75M
Revenue (ttm) n/a
Net Income (ttm) -163.71M
Shares Out 32.74M
EPS (ttm) -5.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13, 2021
Last Price $16.24
Previous Close $16.24
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 16.21 - 16.24
Day's Volume -
52-Week Range 7.15 - 16.26

News

Hide News

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results

3 months ago - Business Wire

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the DSMB

3 months ago - Business Wire

NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Urovant Sciences Ltd. (NASDAQ: UROV) concerning potent...

4 months ago - PRNewsWire

GEMTESA® is the second FDA approval for the Sumitovant Biopharma family of companies in the past weekGEMTESA® is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the fir...

4 months ago - GlobeNewsWire

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for onc...

4 months ago - Business Wire

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Urovant Sciences (...

5 months ago - Business Wire

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--UROV Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint

5 months ago - Business Wire

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study

5 months ago - Business Wire

New York, New York--(Newsfile Corp. - November 18, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsf...

5 months ago - Newsfile Corp

BERWYN, Pa., Nov. 18, 2020 /PRNewswire/ -- RM LAW, P.C. announces an investigation on behalf of Urovant Sciences Ltd. ("Urovant" or the "Company") (NASDAQ: UROV) regarding possible breaches of fiduciary...

5 months ago - PRNewsWire

The acquisition of Urovant Sciences by majority owner Sumitomo significantly undervalues the company's lead asset vibegron. The buyout price implies approximately $250 million in peak sales for vibegron...

5 months ago - Seeking Alpha

NEW YORK, Nov. 13, 2020 /PRNewswire/-- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City...

5 months ago - PRNewsWire

NEW YORK, Nov. 13, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Urovant Sciences Ltd. ("UROV" or the "C...

5 months ago - PRNewsWire

The company's biggest shareholder plans to acquire all of Urovant.

6 months ago - The Motley Fool

Urovant Sciences (UROV) has entered into an acquisition agreement with Sumitovant Biopharma that has UROV stock soaring on Friday. The post UROV Stock: 9 Things to Know About the Urovant Sciences-Sumito...

6 months ago - InvestorPlace

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Urovant Sciences Ltd. (NASDAQ: UROV) to Sumitovant Biopharma Ltd. for $16.25 per shar...

6 months ago - Business Wire

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares

6 months ago - Business Wire

NEW YORK and LONDON and IRVINE, Calif. and BASEL, Switzerland, Nov. 12, 2020 /PRNewswire/ -- Sumitovant Biopharma and Urovant Sciences (Nasdaq: UROV) today announced that they have entered into a defini...

6 months ago - PRNewsWire

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference

6 months ago - Business Wire

Urovant Sciences' (UROV) CEO Jim Robinson on Q2 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results

6 months ago - Business Wire

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results

6 months ago - Business Wire

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals

7 months ago - Business Wire

Urovant's valuation is reasonable when compared to the potential sales peak of Vibegron.

8 months ago - Seeking Alpha

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present at the H.C.

8 months ago - Business Wire

Urovant Sciences Ltd. (UROV) CEO James Robinson on Q1 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Reports Fiscal First Quarter 2020 Results

8 months ago - Business Wire

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results

9 months ago - Business Wire

Urovant Sciences Ltd (UROV) on Q4 2019 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Urovant Sciences Ltd (UROV) CEO James Robinson on Q4 2019 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Urovant Sciences: Still A Hidden Gem With Multiple Catalysts Approaching

11 months ago - Seeking Alpha

Urovant Has Upside Potential Heading Into Vibegron's PDUFA Later This Year

11 months ago - Seeking Alpha

The company has a diversified pipeline in that Vibegron is being explored for several indications that could bring in billions of dollars.

1 year ago - Seeking Alpha

Urovant Sciences' (UROV) CEO Keith Katkin on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Urovant Sciences Is A Hidden Gem With A Blockbuster Drug Likely To Be Approved This Year And 'Short Squeeze' Potential. PT: $43

1 year ago - Seeking Alpha

Urovant Sciences Ltd (NASDAQ: UROV) has submitted a New Drug Application (NDA) to the U.S.

1 year ago - Benzinga

Urovant Sciences Ltd. (UROV) CEO Keith Katkin on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Urovant Sciences Limited (UROV) CEO Keith Katkin on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Finisar falls, Urovant Sciences rises on financial results.

Other stocks mentioned: FNSR
1 year ago - GuruFocus

Urovant Sciences Limited (UROV) CEO Keith Katkin on Q4 2018 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About UROV

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thal... [Read more...]

Industry
Biotechnology
IPO Date
Sep 27, 2018
Stock Exchange
NASDAQ
Ticker Symbol
UROV
Full Company Profile

Financial Performance

Financial Statements